Halyard Health, Inc. (HYH) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Halyard Health, Inc. (NYSE:HYH) from a hold rating to a sell rating in a report issued on Tuesday morning.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

HYH has been the topic of several other reports. BidaskClub raised Halyard Health from a hold rating to a buy rating in a research report on Saturday, August 19th. TheStreet raised Halyard Health from a c rating to a b rating in a research report on Thursday, June 22nd. Stephens raised Halyard Health from an equal weight rating to an overweight rating in a research report on Thursday, August 3rd. Deutsche Bank AG lifted their price target on Halyard Health from $35.00 to $42.00 and gave the stock a buy rating in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $42.25.

Shares of Halyard Health (NYSE HYH) opened at 44.47 on Tuesday. The stock’s 50 day moving average is $45.27 and its 200-day moving average is $40.42. Halyard Health has a 52-week low of $31.59 and a 52-week high of $46.63. The firm has a market cap of $2.08 billion, a P/E ratio of 42.76 and a beta of 1.75.

Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The company’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 EPS. Equities analysts anticipate that Halyard Health will post $1.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Halyard Health, Inc. (HYH) Downgraded to Sell at Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/10/11/halyard-health-inc-hyh-downgraded-to-sell-at-zacks-investment-research-2.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in shares of Halyard Health by 6,362.1% during the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after purchasing an additional 5,847,442 shares during the period. Vanguard Group Inc. increased its position in shares of Halyard Health by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after purchasing an additional 196,367 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Halyard Health by 19.3% during the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after purchasing an additional 507,893 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Halyard Health by 242.8% during the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after purchasing an additional 1,320,735 shares during the period. Finally, State Street Corp increased its position in shares of Halyard Health by 7.5% during the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after purchasing an additional 119,154 shares during the period. 91.02% of the stock is currently

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

HYH has been the topic of several other reports. BidaskClub raised Halyard Health from a hold rating to a buy rating in a research report on Saturday, August 19th. TheStreet raised Halyard Health from a c rating to a b rating in a research report on Thursday, June 22nd. Stephens raised Halyard Health from an equal weight rating to an overweight rating in a research report on Thursday, August 3rd. Deutsche Bank AG lifted their price target on Halyard Health from $35.00 to $42.00 and gave the stock a buy rating in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $42.25.

Shares of Halyard Health (NYSE HYH) opened at 44.47 on Tuesday. The stock’s 50 day moving average is $45.27 and its 200-day moving average is $40.42. Halyard Health has a 52-week low of $31.59 and a 52-week high of $46.63. The firm has a market cap of $2.08 billion, a P/E ratio of 42.76 and a beta of 1.75.

Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The company’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 EPS. Equities analysts anticipate that Halyard Health will post $1.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Halyard Health, Inc. (HYH) Downgraded to Sell at Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/10/11/halyard-health-inc-hyh-downgraded-to-sell-at-zacks-investment-research-2.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in shares of Halyard Health by 6,362.1% during the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after purchasing an additional 5,847,442 shares during the period. Vanguard Group Inc. increased its position in shares of Halyard Health by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after purchasing an additional 196,367 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Halyard Health by 19.3% during the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after purchasing an additional 507,893 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Halyard Health by 242.8% during the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after purchasing an additional 1,320,735 shares during the period. Finally, State Street Corp increased its position in shares of Halyard Health by 7.5% during the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after purchasing an additional 119,154 shares during the period. 91.02% of the stock is currently owned by institutional investors.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply